Digital Health, Artificial Intelligence & Internet of Everything
We empower clients to capitalize on Digital Health, AI, and IoE - accelerating success in these emerging fields. Leveraging robust research capabilities, we deliver strategic insights enabling partners to build winning solutions and gain a competitive edge.
We empower Pharma, Biotech, Healthcare and HealthTech/MedTech companies to capitalize on Digital Health, AI and IoE, accelerating their competitive advantage.
As trusted partners, we provide strategic support spanning areas such as:
- Collaborative projects with BioPharma innovation units and patient solution teams
- Intensive patient-centricity research, placing the end-user at the heart of every solution
- Trend analysis in AI, wearable tech, digital therapeutics, and comprehensive digital health solutions
- Creation and support in AI-powered tool development for enhanced data intelligence
- Joint strategy formulation for competitive digital health and AI initiatives
- Pioneering research on the transformative impact of AI/IoE on healthcare, from “smart” homes to “smart” appliances
With robust research and consulting, we deliver evidence-based solutions, enabling clients to implement winning digital strategies.
Ready to accelerate innovation?
Let’s build winning tech strategies together. Contact us at info@lqventures.com.
October 15, 2026
UEG Week 2026 Preview: Competitive Shifts in Gastroenterology
October 15, 2026
AstraZeneca–HUTCHMED FDA Filing | Lucid Diligence Brief
October 14, 2026
Women’s Health Strategic Roundup: Earlier Intervention | Sep 08 – Oct 13, 2026
October 13, 2026
AI in Healthcare and Digital Health Strategic Roundup: Clinical Adoption | Sep 12 – Oct 12, 2026
October 10, 2026
ECNP 2026 Preview: Emerging Psychiatric Therapies and Competitive Trends
October 9, 2026
HFSA 2026 Preview: Key Heart Failure Treatment Trends And Pipeline
October 9, 2026
Respiratory Strategic Roundup: Earlier Intervention | Sep 4–Oct 7, 2026
October 7, 2026
Cell and Gene Therapy Strategic Roundup | Sep 1 – Oct 6, 2026
October 7, 2026
Strategy Wargaming: What FDA’s Volixibat Signal Means for Ipsen
October 6, 2026
Obesity Strategic Roundup: Beyond GLP-1 Efficacy | Sep 1 – Oct 4 , 2026
October 6, 2026